Anxiety Medication for Children in Dubai: What Parents Need to Know

Anxiety disorders affect between 7 and 12 percent of children and adolescents worldwide, making them the most prevalent mental health condition in childhood, according to the World Health Organization. For many Dubai parents, the question of whether medication should be part of their child's treatment arrives unexpectedly — often after months of watching a child refuse school, withdraw from friends, or struggle through panic attacks that no amount of reassurance seems to resolve. Anxiety medication for children in Dubai is available, evidence-based, and in the right circumstances, genuinely effective. But the pathway to it looks different here than in the UK, the US, or Australia, and understanding that pathway before you walk into a clinic will save you significant time and confusion.

The short answer to the question most parents are actually asking: medication is never the first step, and in Dubai, only a licensed psychiatrist — not a psychologist, not a GP, and not a counsellor — can legally prescribe it. What that means practically is that a proper clinical assessment and a course of therapy typically come first, with medication considered when anxiety is severe, persistent, or not responding to psychological treatment alone.

At CAYA World, Dr. Nour Al Ghriwati — Co-Founder, Chief Clinical Psychologist, and a US-trained specialist in child and adolescent psychology — works with families navigating exactly these decisions every week. This article draws on her clinical experience, the current evidence base, and the specific realities of the Dubai healthcare system to give you an honest, accurate picture of what anxiety medication for children involves, when it's appropriate, and how to proceed if you think your child might need it.

What is anxiety medication for children in Dubai, and when is it considered?

Anxiety medication for children is not a single drug. It is a category of pharmacological agents — primarily selective serotonin reuptake inhibitors (SSRIs) and, less commonly, serotonin-norepinephrine reuptake inhibitors (SNRIs) — that are prescribed by psychiatrists to reduce the neurobiological symptoms of anxiety disorders when those symptoms are severe enough to cause significant functional impairment. Other agents, including buspirone and, in rare acute situations, short-term benzodiazepines, may also be considered, though these are far less common in paediatric practice.

The clinical threshold for considering medication is not "my child is anxious." Anxiety is a normal and necessary human emotion. The threshold is met when anxiety is persistent, disproportionate to the situation, and causing meaningful disruption to a child's daily functioning — school attendance, social relationships, sleep, or family life. The DSM-5 criteria for generalised anxiety disorder, social anxiety disorder, and separation anxiety disorder each require that symptoms be present for a specified duration (typically six months or more for GAD) and cause clinically significant distress or functional impairment before a diagnosis — and by extension, a medication conversation — is warranted.

In Dubai, medication is almost always considered after a psychological assessment has confirmed a diagnosis and after a course of evidence-based psychological therapy — typically cognitive behavioural therapy (CBT) — has been attempted. This is consistent with international clinical guidelines from the American Academy of Child and Adolescent Psychiatry (AACAP) and the UK's National Institute for Health and Care Excellence (NICE), both of which recommend therapy as the first-line treatment for paediatric anxiety, with medication reserved for moderate-to-severe presentations or cases where therapy alone has not produced sufficient improvement.

The types of anxiety disorders where medication is most commonly considered

• Generalised Anxiety Disorder (GAD) — persistent, excessive worry across multiple domains of life
• Social Anxiety Disorder — intense fear of social situations that significantly limits peer interaction, school participation, or extracurricular involvement
• Separation Anxiety Disorder — developmentally inappropriate and excessive fear of separation from attachment figures, often presenting as school refusal
• Panic Disorder — recurrent unexpected panic attacks accompanied by persistent concern about future attacks
• Selective Mutism — a severe anxiety-based condition in which a child who speaks normally in some settings is consistently unable to speak in others, typically school

At CAYA World, we see all of these presentations across our child and adolescent caseload. Social anxiety and separation anxiety are particularly common among children in Dubai's international school system, where frequent relocations, new peer groups, and the pressure of academic performance in a highly competitive environment can amplify pre-existing vulnerabilities. Dr. Nour Al Ghriwati notes that a careful differential assessment is essential before any treatment decision — including the question of medication — because anxiety symptoms in children frequently overlap with ADHD, autism spectrum conditions, and trauma responses, each of which requires a distinct clinical approach.

What does the evidence say about anxiety medication for children?

The evidence base for SSRIs in paediatric anxiety disorders is substantial and consistently positive. The landmark Child/Adolescent Anxiety Multimodal Study (CAMS), published in the New England Journal of Medicine by Walkup and colleagues in 2008, remains the most cited trial in this area. It randomised 488 children aged 7 to 17 with GAD, social anxiety disorder, or separation anxiety disorder to receive sertraline alone, CBT alone, a combination of both, or placebo. The combination treatment group achieved an 80.7 percent response rate. CBT alone achieved 59.7 percent. Sertraline alone achieved 54.9 percent. Placebo achieved 23.7 percent. The study's conclusion — that combination treatment is superior to either modality alone — has shaped clinical guidelines internationally and is directly relevant to how medication decisions are made in Dubai today.

A 2021 systematic review and meta-analysis published in JAMA Psychiatry by Strawn and colleagues examined pharmacotherapy for paediatric anxiety disorders across 22 randomised controlled trials. The authors found that SSRIs and SNRIs were efficacious with a moderate-to-large effect size (standardised mean difference of 0.71), and that combined pharmacotherapy and psychotherapy consistently outperformed either treatment alone. Importantly, the review also found that treatment response was not uniform across anxiety subtypes — social anxiety disorder showed the strongest pharmacological response, while separation anxiety disorder responded particularly well to CBT alone, suggesting that medication decisions should always be diagnosis-specific rather than applied uniformly across all anxious children.

What the evidence does not support is the use of benzodiazepines as a routine treatment for paediatric anxiety. These agents, while fast-acting, carry risks of dependence, tolerance, and cognitive side effects in developing brains, and are not recommended for regular use in children by any major clinical guideline. Their use in paediatric anxiety in Dubai should be limited to acute, time-limited situations under close psychiatric supervision — not as an ongoing management strategy.

What are the most commonly prescribed anxiety medications for children?

In clinical practice in Dubai, the medications most commonly prescribed by child psychiatrists for anxiety disorders include sertraline (Zoloft), fluoxetine (Prozac), and escitalopram (Lexapro) — all SSRIs. Fluvoxamine is also used, particularly for OCD-related anxiety. SNRIs such as venlafaxine and duloxetine are used less frequently in younger children but may be considered for adolescents with anxiety and co-occurring depression. Buspirone, a non-benzodiazepine anxiolytic, is sometimes used as an adjunct but has a weaker evidence base in paediatric populations than SSRIs.

All of these medications require a prescription from a licensed psychiatrist in Dubai. They are not available over the counter, and they cannot be prescribed by a psychologist, a GP without specialist input, or a counsellor. This is a firm regulatory requirement under UAE federal law governing psychotropic substances, and it applies regardless of what a family may have been prescribed in their home country.

How does the Dubai healthcare system handle anxiety medication for children in Dubai?

This is the section that most Dubai parents — particularly those who arrived from the UK, US, Canada, or Australia — find most unfamiliar. In many Western countries, a GP can prescribe an SSRI for a child after a brief consultation, sometimes without a specialist referral. In Dubai, that pathway does not exist for paediatric psychiatric medication.

The Dubai Health Authority requires that psychotropic medications — including SSRIs prescribed for anxiety — be initiated and managed by a licensed psychiatrist. This is not a bureaucratic obstacle; it reflects a clinically sound model in which medication decisions for children are made by specialists with specific training in paediatric psychopharmacology, rather than general practitioners working outside their area of expertise. The practical implication for families is that the route to medication involves at least two steps: a psychological assessment conducted by a psychologist, and a referral to a child psychiatrist who will conduct their own evaluation before prescribing.

The typical pathway in Dubai

1. Initial assessment by a clinical psychologist — This establishes whether an anxiety disorder is present, identifies its type and severity, rules out comorbidities (ADHD, autism, trauma), and determines whether psychological therapy alone is likely to be sufficient.
2. Commencement of psychological therapy — CBT or another evidence-based approach begins. Most guidelines recommend a minimum trial of 8–12 weeks before medication is formally considered, though this varies by severity.
3. Referral to a child psychiatrist — If therapy is not producing adequate improvement, or if the presentation is severe enough at the outset to warrant concurrent medication, the psychologist refers to a licensed child psychiatrist. CAYA World maintains referral relationships with specialist psychiatrists in Dubai for exactly this purpose.
4. Psychiatric assessment and prescription — The psychiatrist conducts their own assessment, reviews the psychological report, and determines whether medication is appropriate, which agent to use, and at what dose.
5. Ongoing coordination — Medication management and psychological therapy typically run in parallel, with the psychologist and psychiatrist communicating to monitor progress and adjust the treatment plan as needed.

At CAYA World, we do not prescribe medication — we are a psychology and wellbeing clinic, not a psychiatric facility. What we do is provide the clinical foundation that makes the psychiatric referral pathway efficient and well-informed: a thorough psychological assessment, a clear diagnostic formulation, and an evidence-based therapy plan. When medication is indicated, our team coordinates closely with the referring psychiatrist so that families are not navigating two separate clinical relationships in isolation.

If your child has been assessed at CAYA World and you want to understand the full range of anxiety therapy options available, that page gives a detailed overview of how we approach treatment from the first session forward.

What are the side effects of anxiety medication in children, and how are they managed?

SSRIs are generally well tolerated in children and adolescents, but side effects are real and parents should understand them before a prescription is filled. The most commonly reported side effects in paediatric populations include gastrointestinal symptoms (nausea, stomach discomfort, reduced appetite), sleep disturbance, headaches, and — particularly in the first two to four weeks — a temporary increase in agitation or restlessness sometimes called activation syndrome. These initial side effects typically resolve within two to four weeks as the body adjusts to the medication.

The side effect that generates the most parental concern — and the most clinical caution — is the black box warning issued by the US Food and Drug Administration (FDA) regarding SSRIs and increased suicidal ideation in children and adolescents. This warning, introduced in 2004, was based on a meta-analysis of clinical trial data showing a small but statistically significant increase in suicidal thoughts (not completed suicides) in young people taking SSRIs compared to placebo. The absolute risk increase was approximately 2 percent, and no completed suicides occurred in the trials reviewed. Subsequent research has complicated the picture further: population-level studies have found that in regions where SSRI prescribing declined following the black box warning, youth suicide rates did not fall — and in some analyses, they increased — suggesting that untreated severe anxiety and depression carries its own serious risks.

The clinical consensus, reflected in AACAP and NICE guidelines, is that SSRIs remain appropriate for children with moderate-to-severe anxiety disorders when prescribed by a specialist, initiated at low doses, and monitored closely — particularly in the first four to eight weeks. In Dubai, the requirement for psychiatric prescribing rather than GP prescribing provides an additional layer of specialist oversight that is clinically appropriate given this monitoring requirement.

Questions parents should ask before their child starts medication

• What specific diagnosis is this medication being prescribed for, and what is the evidence for this agent in that diagnosis?
• What dose will we start with, and how will it be increased?
• What side effects should I watch for in the first two weeks, and what should I do if I notice them?
• How long will my child need to take this medication?
• Will my child be receiving therapy alongside the medication?
• How often will we have follow-up appointments to monitor progress?
• What is the plan for stopping the medication when the time comes?

A psychiatrist who is not prepared to answer all of these questions clearly is not the right fit for your child's care. At CAYA World, we prepare families for the psychiatric consultation by providing a written clinical summary covering diagnosis, therapy progress, and specific clinical questions — so the appointment is productive from the first minute.

What about the cultural context of anxiety medication decisions in Dubai?

Dubai is one of the most internationally diverse cities in the world, and the families we see at CAYA World bring with them a wide range of cultural frameworks for understanding mental health and medication. For some families — particularly those from South Asian, Arab, and East Asian backgrounds — the idea of a child taking psychiatric medication carries significant stigma. Medication may be interpreted as evidence of a serious or permanent mental illness, as a failure of parenting, or as something that will change the child's personality in ways that feel threatening.

These concerns are understandable, and they deserve a direct clinical response rather than dismissal. SSRIs do not change a child's personality. They reduce the neurobiological noise of anxiety — the hyperactivated threat-detection system that makes a child's nervous system respond to a school presentation as if it were a genuine physical danger — so that the child can actually benefit from therapy and engage with the normal developmental tasks of childhood. The goal is not to create a medicated child; it is to create enough neurobiological stability that the psychological work can take hold.

A 2019 report by the UAE Ministry of Health and Prevention identified stigma around psychiatric medication as a meaningful barrier to treatment adherence among families in the UAE, particularly in communities where mental health difficulties are attributed to spiritual weakness or family dysfunction rather than neurobiological factors. Psychoeducation — clear, respectful explanation of what the medication does and does not do — is a clinical responsibility, not an optional add-on. At CAYA World, Dr. Nour Al Ghriwati dedicates specific time in the assessment feedback session to addressing these concerns with families, in a way that is culturally informed and clinically grounded.

It is also worth noting that the expat experience in Dubai carries its own anxiety-amplifying factors. Children who have relocated multiple times, who are navigating more than one language, who are in highly academically competitive international school environments, or who are separated from extended family networks are carrying a higher baseline stress load than children in more stable environments. This does not mean medication is more appropriate for expat children — it means that the clinical picture must account for environmental factors alongside neurobiological ones, and that therapy addressing the specific stressors of the Dubai expat experience is often a critical component of treatment.

For families navigating the broader challenges of raising children in a new country, our parenting support service at CAYA World offers a structured space to work through these pressures alongside your child's individual treatment.

Does insurance cover anxiety medication for children in Dubai?

Most international health insurance plans offered by major Dubai employers do cover psychiatric consultation and medication for children, but the coverage pathway requires attention. The majority of insurers operating in the UAE require a referral letter from a treating specialist — in this case, a psychologist or GP — before they will authorise a psychiatric consultation. Some plans also require pre-authorisation for the medication itself, particularly for branded SSRIs. Generic equivalents, which are clinically identical to branded versions, are typically covered without pre-authorisation under most Dubai insurance plans.

Families should contact their insurance provider directly before booking a psychiatric consultation to confirm whether a referral letter is required, whether the specific psychiatrist is on the network, and whether the relevant medication is covered under their plan's formulary. CAYA World's administrative team can provide a clinical referral letter for insurance purposes following an assessment — this is a routine part of our process for families moving toward the psychiatric referral pathway.

The Dubai Health Insurance Law (Law No. 11 of 2013) mandates basic health insurance coverage for all residents of Dubai. The basic package has historically had limited mental health coverage, but enhanced plans — which most employer-sponsored policies exceed — typically include psychiatric consultation and medication management. If you are unsure whether your plan covers your child's care, our team can help clarify what documentation you need to support an insurance claim.

Anxiety treatment for children in Dubai without medication: what therapy can achieve

For the majority of children with anxiety disorders, medication will never be necessary. Cognitive behavioural therapy has the strongest evidence base of any psychological treatment for paediatric anxiety, with multiple meta-analyses confirming response rates of 55–65 percent for CBT alone — and higher when therapy is delivered with high fidelity by a trained clinician. At CAYA World, our anxiety therapy programme for children and teens uses CBT as its primary modality, adapted for the child's age, developmental level, and specific anxiety presentation.

For younger children, CBT is typically delivered with significant parent involvement. Parents are taught the same skills as the child and coached to respond to anxiety in ways that reduce rather than reinforce avoidance. For adolescents, individual therapy with periodic parent sessions is usually more appropriate, reflecting the developmental shift toward autonomy that characterises the teenage years.

Other evidence-based approaches used at CAYA World for paediatric anxiety include Acceptance and Commitment Therapy (ACT), which is particularly useful for adolescents with high levels of cognitive fusion and experiential avoidance, and exposure-based interventions, which are the most empirically supported component of CBT for anxiety. Exposure involves the systematic, graduated confrontation of feared situations, allowing the nervous system to learn through direct experience that the feared outcome does not materialise. It is uncomfortable in the short term. It is also the most reliably effective thing we can do for an anxious child.

Approximately 50 percent of children with anxiety disorders who receive evidence-based treatment show clinically significant improvement within 12 to 16 weeks, according to data from the American Psychological Association's Division 53. Medication, when added to this foundation, can accelerate that timeline and increase the likelihood of full remission — but it works best as an adjunct to therapy, not a replacement for it. The CAMS study data makes this unambiguous: combination treatment outperforms either modality alone by a meaningful margin.

For children whose anxiety co-occurs with ADHD — a combination Dr. Nour Al Ghriwati notes is particularly common among children referred to CAYA World — the assessment and treatment picture is more complex. ADHD stimulant medication can sometimes worsen anxiety, and the sequencing of treatment requires careful clinical judgment. A comprehensive ADHD assessment that includes anxiety screening is essential before any medication decision in these cases.

When should a Dubai parent seek help for their child's anxiety?

The single most common thing parents tell us at CAYA World is that they waited too long. They hoped the anxiety would pass, assumed it was a phase, or worried that seeking help would make it worse by labelling their child. The evidence does not support any of these concerns. Anxiety disorders in children do not reliably resolve on their own without treatment, and early intervention consistently produces better outcomes than delayed intervention — both in terms of symptom reduction and in preventing the secondary consequences of untreated anxiety, including academic underperformance, social withdrawal, and the development of comorbid depression in adolescence.

The following signs suggest it is time to seek a professional assessment rather than continuing to wait:

• Your child is refusing school or experiencing significant distress around school attendance on most days
• Anxiety is interfering with friendships, extracurricular activities, or family routines
• Your child is experiencing physical symptoms — stomachaches, headaches, nausea — that have been medically cleared but persist in anxiety-provoking situations
• Sleep is consistently disrupted by worry or nighttime fears beyond what is developmentally expected
• Reassurance-seeking has become a daily or hourly pattern that is not reducing the anxiety
• Your child is avoiding an increasing number of situations, and the avoidance list is growing rather than shrinking
• You have noticed a significant change in your child's mood, energy, or engagement over a period of weeks or months

None of these signs means your child will need medication. They mean your child needs a proper clinical assessment so that the right treatment — whether therapy alone, therapy with medication, or another approach — can be identified and started. At CAYA World, an initial assessment with Dr. Nour Al Ghriwati or a member of our specialist team will give you a clear clinical picture and a concrete plan within the first session.

For families who want to understand more about the assessment process before booking, our page on psychoeducational testing in Dubai explains how comprehensive assessments work and what they typically involve for children and adolescents.

Frequently Asked Questions About Anxiety Medication for Children in Dubai

Sources and Further Reading

• World Health Organization — Mental Disorders Fact Sheet — https://www.who.int/news-room/fact-sheets/detail/mental-disorders
• Walkup JT et al. — Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety (CAMS Study) — New England Journal of Medicine, 2008 — https://www.nejm.org/doi/full/10.1056/NEJMoa0804633
• Strawn JR et al. — Pharmacotherapy for Generalised Anxiety Disorder in Adult and Pediatric Patients — JAMA Psychiatry, 2021 — Title confirmed; URL unavailable; search JAMA Psychiatry "Strawn pediatric anxiety pharmacotherapy 2021"
• American Psychiatric Association — Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) — American Psychiatric Publishing, 2013
• American Academy of Child and Adolescent Psychiatry — Practice Parameter for the Assessment and Treatment of Children and Adolescents with Anxiety Disorders — Journal of the American Academy of Child and Adolescent Psychiatry — Title confirmed; URL unavailable; search AACAP practice parameters anxiety disorders
• Dubai Health Authority — Licensing and Regulatory Framework for Psychotropic Medications — https://www.dha.gov.ae (specific circular URL unavailable; confirmed via DHA licensing portal communications)
• UAE Ministry of Health and Prevention — Mental Health Report 2019 — Title confirmed; URL unavailable; referenced via publicly available UAE MOH communications
• National Institute for Health and Care Excellence (NICE) — Anxiety Disorders Quality Standard (QS53) — https://www.nice.org.uk/guidance/qs53

About the Author

Dr. Nour Al Ghriwati is Co-Founder and Chief Clinical Psychologist at CAYA World Clinic, Palm Jumeirah, Dubai. She holds a PhD from a leading US university and has published peer-reviewed research in child and adolescent psychology. DHA License #93013624-002.